

In the Claims

1-10. (canceled)

11. (currently amended) A method for the treatment of liver fibrotic inflammatory and/or liver autoimmune diseases reducing serum alanine aminotransferase (ALT) in a subject with hepatitis comprising the administration of an effective amount of a CC-chemokine mutant having reduced glycosaminoglycan (GAG)-binding-GAG-binding activity to a patient, wherein the CC-chemokine mutant is CCL3 / MIP-1alpha, CCL4 / MIP-1beta, or CCL5 / RANTES a triple 40's CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) mutant.

12. (currently amended) The method according to claim 11, wherein the CC-chemokine is CCL5 / RANTES and the mutant comprises SEQ ID NO: 1 is triple 40's RANTES mutant (SEQ ID NO: 1).

13-19 (canceled).

20. (currently amended) The method according to claim 11, wherein the CC-chemokine mutant further comprises an amino acid sequence belonging to a protein sequence other than the corresponding CC-chemokine immunoglobulin constant region.

21. (currently amended) The method according to claim 11, wherein the CC-chemokine mutant is in the form of an active precursor, salt, derivative, conjugate or complex.

22. (currently amended) The method according to claim 11, wherein the liver disease is an alcoholic liver disease, a viral hepatitis, or hepatitis is an autoimmune hepatitis.

23 (new). The method according to claim 11, further comprising the measurement of serum ALT levels in said patient.

24. (new) A method for reducing serum alanine aminotransferase (ALT) levels in a patient comprising measuring serum ALT levels in the patient and administering an effective amount of a CC-chemokine mutant having reduced glycosaminoglycan (GAG)-binding activity to a patient, wherein the CC-chemokine mutant is a triple 40's CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) mutant.

25. (new) The method according to claim 24, wherein the mutant comprises SEQ ID NO: 1.

26. (new) The method according to claim 24, wherein the mutant further comprises immunoglobulin constant region.